Treatment pattern and frequency of serum TSH measurement in users of different levothyroxine formulations

a population-based study during the years 2009–2015

Rosarita Ferrara, Valentina Ientile, Vincenzo Arcoraci, Carmen Ferrajolo, Carlo Piccinni, Andrea Fontana, Salvatore Benvenga, Gianluca Trifirò

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Several conditions can modify the intestinal absorption of levothyroxine tablets, with potential consequences on their therapeutic effect. Pre-dosed ampoules and oral drops have been recently made available to overcome this limitation. Aims: To describe the pattern of use of different formulations of levothyroxine in a general population of Southern Italy and to perform an exploratory analysis investigating the effect of switching from levothyroxine tablets to oral liquid formulations. Methods: Data were extracted from the Caserta Local Health Unit database. All patients receiving at least one levothyroxine prescription during the years 2009–2015 were identified. 1-year incidence of use of formulation-specific levothyroxine was calculated. Switchers between levothyroxine tablets and oral liquid formulations were identified and the frequency of thyroid-stimulating hormone measurement within 2 years prior and after the switch date was explored. Results: Overall, 56,354 levothyroxine users were included in the study. Of these, 55,147 patients received at least one prescription for tablets (97.9%), 1867 pre-dosed ampoules (3.3%) and 1550 oral drops (2.8%). The proportion of levothyroxine users receiving oral liquid formulations slightly increased over time. Patients switching from tablets to oral liquid formulations showed a statistically significant reduction in the number of thyroid-stimulating hormone measurements after switching from tablets, especially in presence of drugs interacting with levothyroxine potentially altering its absorption. Conclusions: Use of levothyroxine oral liquid formulations is increasing over time even though their use is still limited in a general population of Southern Italy. Our exploratory analysis showed that the frequency of thyroid-stimulating hormone measurement was reduced in patients switching from levothyroxine tablet to new formulations.

Original languageEnglish
Pages (from-to)143-152
Number of pages10
JournalEndocrine
Volume58
Issue number1
DOIs
Publication statusPublished - Oct 1 2017

Fingerprint

Thyroxine
Tablets
Serum
Population
Thyrotropin
Therapeutics
Italy
Prescriptions
Intestinal Absorption
Therapeutic Uses
Databases
Incidence
Health

Keywords

  • Absorption
  • Formulations
  • Levothyroxine
  • Switching
  • TSH

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Treatment pattern and frequency of serum TSH measurement in users of different levothyroxine formulations : a population-based study during the years 2009–2015. / Ferrara, Rosarita; Ientile, Valentina; Arcoraci, Vincenzo; Ferrajolo, Carmen; Piccinni, Carlo; Fontana, Andrea; Benvenga, Salvatore; Trifirò, Gianluca.

In: Endocrine, Vol. 58, No. 1, 01.10.2017, p. 143-152.

Research output: Contribution to journalArticle

Ferrara, R, Ientile, V, Arcoraci, V, Ferrajolo, C, Piccinni, C, Fontana, A, Benvenga, S & Trifirò, G 2017, 'Treatment pattern and frequency of serum TSH measurement in users of different levothyroxine formulations: a population-based study during the years 2009–2015', Endocrine, vol. 58, no. 1, pp. 143-152. https://doi.org/10.1007/s12020-017-1242-4
Ferrara, Rosarita ; Ientile, Valentina ; Arcoraci, Vincenzo ; Ferrajolo, Carmen ; Piccinni, Carlo ; Fontana, Andrea ; Benvenga, Salvatore ; Trifirò, Gianluca. / Treatment pattern and frequency of serum TSH measurement in users of different levothyroxine formulations : a population-based study during the years 2009–2015. In: Endocrine. 2017 ; Vol. 58, No. 1. pp. 143-152.
@article{8965cbcd7ee541f3981fd9c0f0a18092,
title = "Treatment pattern and frequency of serum TSH measurement in users of different levothyroxine formulations: a population-based study during the years 2009–2015",
abstract = "Background: Several conditions can modify the intestinal absorption of levothyroxine tablets, with potential consequences on their therapeutic effect. Pre-dosed ampoules and oral drops have been recently made available to overcome this limitation. Aims: To describe the pattern of use of different formulations of levothyroxine in a general population of Southern Italy and to perform an exploratory analysis investigating the effect of switching from levothyroxine tablets to oral liquid formulations. Methods: Data were extracted from the Caserta Local Health Unit database. All patients receiving at least one levothyroxine prescription during the years 2009–2015 were identified. 1-year incidence of use of formulation-specific levothyroxine was calculated. Switchers between levothyroxine tablets and oral liquid formulations were identified and the frequency of thyroid-stimulating hormone measurement within 2 years prior and after the switch date was explored. Results: Overall, 56,354 levothyroxine users were included in the study. Of these, 55,147 patients received at least one prescription for tablets (97.9{\%}), 1867 pre-dosed ampoules (3.3{\%}) and 1550 oral drops (2.8{\%}). The proportion of levothyroxine users receiving oral liquid formulations slightly increased over time. Patients switching from tablets to oral liquid formulations showed a statistically significant reduction in the number of thyroid-stimulating hormone measurements after switching from tablets, especially in presence of drugs interacting with levothyroxine potentially altering its absorption. Conclusions: Use of levothyroxine oral liquid formulations is increasing over time even though their use is still limited in a general population of Southern Italy. Our exploratory analysis showed that the frequency of thyroid-stimulating hormone measurement was reduced in patients switching from levothyroxine tablet to new formulations.",
keywords = "Absorption, Formulations, Levothyroxine, Switching, TSH",
author = "Rosarita Ferrara and Valentina Ientile and Vincenzo Arcoraci and Carmen Ferrajolo and Carlo Piccinni and Andrea Fontana and Salvatore Benvenga and Gianluca Trifir{\`o}",
year = "2017",
month = "10",
day = "1",
doi = "10.1007/s12020-017-1242-4",
language = "English",
volume = "58",
pages = "143--152",
journal = "Endocrine",
issn = "1355-008X",
publisher = "Humana Press Inc.",
number = "1",

}

TY - JOUR

T1 - Treatment pattern and frequency of serum TSH measurement in users of different levothyroxine formulations

T2 - a population-based study during the years 2009–2015

AU - Ferrara, Rosarita

AU - Ientile, Valentina

AU - Arcoraci, Vincenzo

AU - Ferrajolo, Carmen

AU - Piccinni, Carlo

AU - Fontana, Andrea

AU - Benvenga, Salvatore

AU - Trifirò, Gianluca

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Background: Several conditions can modify the intestinal absorption of levothyroxine tablets, with potential consequences on their therapeutic effect. Pre-dosed ampoules and oral drops have been recently made available to overcome this limitation. Aims: To describe the pattern of use of different formulations of levothyroxine in a general population of Southern Italy and to perform an exploratory analysis investigating the effect of switching from levothyroxine tablets to oral liquid formulations. Methods: Data were extracted from the Caserta Local Health Unit database. All patients receiving at least one levothyroxine prescription during the years 2009–2015 were identified. 1-year incidence of use of formulation-specific levothyroxine was calculated. Switchers between levothyroxine tablets and oral liquid formulations were identified and the frequency of thyroid-stimulating hormone measurement within 2 years prior and after the switch date was explored. Results: Overall, 56,354 levothyroxine users were included in the study. Of these, 55,147 patients received at least one prescription for tablets (97.9%), 1867 pre-dosed ampoules (3.3%) and 1550 oral drops (2.8%). The proportion of levothyroxine users receiving oral liquid formulations slightly increased over time. Patients switching from tablets to oral liquid formulations showed a statistically significant reduction in the number of thyroid-stimulating hormone measurements after switching from tablets, especially in presence of drugs interacting with levothyroxine potentially altering its absorption. Conclusions: Use of levothyroxine oral liquid formulations is increasing over time even though their use is still limited in a general population of Southern Italy. Our exploratory analysis showed that the frequency of thyroid-stimulating hormone measurement was reduced in patients switching from levothyroxine tablet to new formulations.

AB - Background: Several conditions can modify the intestinal absorption of levothyroxine tablets, with potential consequences on their therapeutic effect. Pre-dosed ampoules and oral drops have been recently made available to overcome this limitation. Aims: To describe the pattern of use of different formulations of levothyroxine in a general population of Southern Italy and to perform an exploratory analysis investigating the effect of switching from levothyroxine tablets to oral liquid formulations. Methods: Data were extracted from the Caserta Local Health Unit database. All patients receiving at least one levothyroxine prescription during the years 2009–2015 were identified. 1-year incidence of use of formulation-specific levothyroxine was calculated. Switchers between levothyroxine tablets and oral liquid formulations were identified and the frequency of thyroid-stimulating hormone measurement within 2 years prior and after the switch date was explored. Results: Overall, 56,354 levothyroxine users were included in the study. Of these, 55,147 patients received at least one prescription for tablets (97.9%), 1867 pre-dosed ampoules (3.3%) and 1550 oral drops (2.8%). The proportion of levothyroxine users receiving oral liquid formulations slightly increased over time. Patients switching from tablets to oral liquid formulations showed a statistically significant reduction in the number of thyroid-stimulating hormone measurements after switching from tablets, especially in presence of drugs interacting with levothyroxine potentially altering its absorption. Conclusions: Use of levothyroxine oral liquid formulations is increasing over time even though their use is still limited in a general population of Southern Italy. Our exploratory analysis showed that the frequency of thyroid-stimulating hormone measurement was reduced in patients switching from levothyroxine tablet to new formulations.

KW - Absorption

KW - Formulations

KW - Levothyroxine

KW - Switching

KW - TSH

UR - http://www.scopus.com/inward/record.url?scp=85011632767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011632767&partnerID=8YFLogxK

U2 - 10.1007/s12020-017-1242-4

DO - 10.1007/s12020-017-1242-4

M3 - Article

VL - 58

SP - 143

EP - 152

JO - Endocrine

JF - Endocrine

SN - 1355-008X

IS - 1

ER -